Biocon Biologics completes acquisition of Viatris biosimilars biz for $3.3 bn
Biocon Biologics, Viatris get all key approvals from global regulators, including US FTC, CCI, RBI, and investors. Biocon Ltd’s stake in Biocon Biologics to rise to 68%.
Biocon Biologics, Viatris get all key approvals from global regulators, including US FTC, CCI, RBI, and investors. Biocon Ltd’s stake in Biocon Biologics to rise to 68%.
Viatris will receive $2 billion in cash and up to $335 million as additional payments expected to be paid in 2024.
Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products.